ProCE Banner Activity

GARNET: Update From Phase I Trial of Dostarlimab in Patients With Advanced or Recurrent dMMR/MSI-H or pMMR/MSS Endometrial Cancer

Slideset Download
Conference Coverage
Dostarlimab was associated with overall response rates of 45.4% and 15.4%, including durable responses, in dMMR/MSI-H and pMMR/MSS advanced/recurrent endometrial cancer.

Released: June 10, 2022

Expiration: June 09, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab